Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced that its off-the-shelf placenta-derived cell therapies will be the focus of presentations at upcoming investor and medical conferences.
“We recently reported interim top-line results from our Phase I clinical trials demonstrating that PLX-PAD is safe, well tolerated and had improved the quality of life of CLI patients in the studies”
Chaya Mazouz, the company's vice president of clinical and regulatory affairs, will present information about the regulatory study design considerations for PLX-PAD, the company's lead cell therapy candidate for the treatment of critical limb ischemia (CLI), at 11 a.m. EDT on May 24 at the International Society for Cellular Therapy's (ISCT) 16th Annual Meeting in Philadelphia. She will also participate in a case study panel discussion: "Global Regulatory Perspectives Workshop", on May 23 at 3:15 p.m. EDT. Also at the meeting, Frida Grynspan, Pluristem's vice president of research and development, will present an overview of the immunological profile of CLI patients following the intramuscular administration of PLX-PAD. Her presentation will take place at 10:45 a.m. EDT on May 25.
"We recently reported interim top-line results from our Phase I clinical trials demonstrating that PLX-PAD is safe, well tolerated and had improved the quality of life of CLI patients in the studies," said Zami Aberman, Pluristem's chairman and CEO. "With PLX-PAD, we have the unique opportunity to utilize a single source of cells, the placenta, to treat an unlimited number of CLI patients. Our presentations at the ISCT Annual Meeting and other conferences will highlight the potential of PLX-PAD as well as our core technology that enables the cost-effective development of cell therapies derived from the human placenta."
At 1:15 p.m. EDT on June 1, Mr. Aberman will participate in a plenary session about the allogeneic approaches of cell therapy at the Stem Cell Investor & Executive Networking Conference Event (SCIENCE) in New York. Hosted by National Securities Corporation and MD Becker Partners, SCIENCE is designed to unite investors with industry executives to exchange information and highlight opportunities in the stem cell universe. The event will bring together researchers, clinicians, business leaders, key investors and other stakeholders in the cell therapy space.
Researchers discover how mutations disrupt protein splicing and cause disease